Diana Lewez Hanna, MD

Assistant Professor of Clinical Medicine

Image of Diana Lewez Hanna, MD
Is this your profile? Click to edit

Overview

Dr. Hanna’s research interests include investigation of predictive and prognostic biomarkers in gastrointestinal malignancies and clinical trial protocol development with Dr. Heinz-Josef Lenz.

Dr. Hanna earned her medical degree from University of California, Davis. She then went on to complete her Hematology/Oncology Fellowship at USC, where she served as Chief Fellow.

Awards

  • Division of Oncology, USC: Chief Fellow, 2014-2015
  • University of California, Davis: Professionalism of the Year in Internal Medicine Award, 2012
  • Phi Sigma Honor Society, 2005
  • Phi Kappa Phi Honor Society, 2005

Publications

  • Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study Lancet Oncol. 2022 Dec; 23(12):1558-1570. . View in PubMed
  • Cabozantinib: An evolving therapy for hepatocellular carcinoma Cancer Treat Rev. 2021 Jul; 98:102221. . View in PubMed
  • The time to offer treatments for COVID-19 Expert Opin Investig Drugs. 2021 May; 30(5):505-518. . View in PubMed
  • The Importance of Understanding the Stages of COVID-19 in Treatment and Trials AIDS Rev. 2021 02 08; 23(1):40-47. . View in PubMed
  • Polymorphisms within Immune Regulatory Pathways Predict Cetuximab Efficacy and Survival in Metastatic Colorectal Cancer Patients Cancers (Basel). 2020 Oct 13; 12(10). . View in PubMed
  • How we treat left-sided vs right-sided colon cancer Clin Adv Hematol Oncol. 2020 May; 18(5):253-257. . View in PubMed
  • Epidermal growth factor receptor mRNA expression: A potential molecular escape mechanism from regorafenib Cancer Sci. 2020 Feb; 111(2):441-450. . View in PubMed
  • A polymorphism within the R-spondin 2 gene predicts outcome in metastatic colorectal cancer patients treated with FOLFIRI/bevacizumab: data from FIRE-3 and TRIBE trials Eur J Cancer. 2020 05; 131:89-97. . View in PubMed
  • Single cell correlation analysis of liquid and solid biopsies in metastatic colorectal cancer Oncotarget. 2019 Dec 17; 10(66):7016-7030. . View in PubMed
  • Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study Clin Colorectal Cancer. 2018 09; 17(3):e471-e488. . View in PubMed
  • Prognostic impact of FOXF1 polymorphisms in gastric cancer patients Pharmacogenomics J. 2018 04; 18(2):262-269. . View in PubMed
  • Clinical relevance of EMT and stem-like gene expression in circulating tumor cells of metastatic colorectal cancer patients Pharmacogenomics J. 2018 01; 18(1):29-34. . View in PubMed
  • A Polymorphism within the Vitamin D Transporter Gene Predicts Outcome in Metastatic Colorectal Cancer Patients Treated with FOLFIRI/Bevacizumab or FOLFIRI/Cetuximab Clin Cancer Res. 2018 02 15; 24(4):784-793. . View in PubMed
  • Colorectal cancer: epigenetic alterations and their clinical implications Biochim Biophys Acta Rev Cancer. 2017 Dec; 1868(2):439-448. . View in PubMed
  • DNA mismatch repair deficiency and hereditary syndromes in Latino patients with colorectal cancer Cancer. 2017 Oct 01; 123(19):3732-3743. . View in PubMed
  • CXCR4 polymorphism predicts progression-free survival in metastatic colorectal cancer patients treated with first-line bevacizumab-based chemotherapy Pharmacogenomics J. 2017 12; 17(6):543-550. . View in PubMed
  • Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trials Eur J Cancer. 2017 05; 77:13-20. . View in PubMed
  • Single nucleotide polymorphisms in the IGF-IRS pathway are associated with outcome in mCRC patients enrolled in the FIRE-3 trial Int J Cancer. 2017 07 15; 141(2):383-392. . View in PubMed
  • Impact of sex, age, and ethnicity/race on the survival of patients with rectal cancer in the United States from 1988 to 2012 Oncotarget. 2016 Aug 16; 7(33):53668-53678. . View in PubMed
  • Molecular Pathways: Cachexia Signaling-A Targeted Approach to Cancer Treatment Clin Cancer Res. 2016 Aug 15; 22(16):3999-4004. . View in PubMed
  • Novel therapeutics in metastatic colorectal cancer: molecular insights and pharmacogenomic implications Expert Rev Clin Pharmacol. 2016 Aug; 9(8):1091-108. . View in PubMed
  • Expression of Genes Involved in Vascular Morphogenesis and Maturation Predicts Efficacy of Bevacizumab-Based Chemotherapy in Patients Undergoing Liver Resection Mol Cancer Ther. 2016 11; 15(11):2814-2821. . View in PubMed
  • TWIST1 Polymorphisms Predict Survival in Patients with Metastatic Colorectal Cancer Receiving First-Line Bevacizumab plus Oxaliplatin-Based Chemotherapy Mol Cancer Ther. 2016 06; 15(6):1405-11. . View in PubMed
  • Prognostic Impact of IL6 Genetic Variants in Patients with Metastatic Colorectal Cancer Treated with Bevacizumab-Based Chemotherapy Clin Cancer Res. 2016 07 01; 22(13):3218-26. . View in PubMed
  • ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016 ESMO Open. 2016; 1(5):e000097. . View in PubMed
  • Cytokeratin-20 and Survivin-Expressing Circulating Tumor Cells Predict Survival in Metastatic Colorectal Cancer Patients by a Combined Immunomagnetic qRT-PCR Approach Mol Cancer Ther. 2015 Oct; 14(10):2401-8. . View in PubMed
  • Distinct gene expression profiles of proximal and distal colorectal cancer: implications for cytotoxic and targeted therapy Pharmacogenomics J. 2015 Aug; 15(4):354-62. . View in PubMed
  • Impact of sex on the survival of patients with hepatocellular carcinoma: a Surveillance, Epidemiology, and End Results analysis Cancer. 2014 Dec 01; 120(23):3707-16. . View in PubMed
  • Plastin polymorphisms predict gender- and stage-specific colon cancer recurrence after adjuvant chemotherapy Mol Cancer Ther. 2014 Feb; 13(2):528-39. . View in PubMed
  • Biomolecular markers of cancer-associated thromboembolism Crit Rev Oncol Hematol. 2013 Oct; 88(1):19-29. . View in PubMed